2002
Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users?
Kapadia F, Vlahov D, Jarlais D, Strathdee S, Ouellet L, Kerndt P, E E, Williams I, Garfein R. Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users? Epidemiology 2002, 13: 738-741. PMID: 12410020, DOI: 10.1097/00001648-200211000-00023.Peer-Reviewed Original ResearchConceptsInjection drug usersAnti-HCV seroconversionHepatitis C virusDrug usersOdds ratioBleach useYoung adult injection drug usersSeronegative injection drug usersMajor public health problemAdult injection drug usersBleach disinfectionHepatitis C infectionProspective cohort studyCase-control studyConditional logistic regressionPublic health problemCessation of injectionsC infectionHCV infectionCohort studyC virusProtective effectHealth problemsSeroconversionLogistic regression
2000
Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus
Shah N, Celentano D, Vlahov D, Stambolis V, Johnson L, Nelson K, Strathdee S. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS 2000, 14: 2035-2043. PMID: 10997409, DOI: 10.1097/00002030-200009080-00020.Peer-Reviewed Original ResearchMeSH KeywordsAdultBaltimoreCohort StudiesFemaleHealth Services AccessibilityHIV AntibodiesHIV InfectionsHIV SeronegativityHIV SeropositivityHumansMaleMethadoneMiddle AgedNeedle-Exchange ProgramsProspective StudiesRisk-TakingSocioeconomic FactorsSubstance Abuse Treatment CentersSubstance Abuse, IntravenousConceptsMethadone maintenance treatment programInjection drug usersMaintenance treatment programNeedle exchange programsHIV serostatusHIV-seronegative injection drug usersSeronegative injection drug usersHIV-negative injection drug usersTreatment programHIV-seropositive participantsHealth care providersTreatment slotsNeedle exchange program participantsAfrican AmericansHIV testProspective cohortCare providersDrug usersProgram attendanceOlder ageCertain subgroupsVulnerable populationsSimilar proportionsBehavioral factorsEnrollment
1995
Human Immunodeficiency Virus Type 1 env and p17gag Sequence Variation in Polymerase Chain Reaction-Positive, Seronegative Injection Drug Users
Markham R, Yu X, Farzadegan H, Ray S, Vlahov D. Human Immunodeficiency Virus Type 1 env and p17gag Sequence Variation in Polymerase Chain Reaction-Positive, Seronegative Injection Drug Users. The Journal Of Infectious Diseases 1995, 171: 797-804. PMID: 7706805, DOI: 10.1093/infdis/171.4.797.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceBase SequenceCross-Sectional StudiesDNA, ViralFemaleGag Gene Products, Human Immunodeficiency VirusGene Products, envGene Products, gagGenes, envGenes, gagGenetic VariationHIV AntigensHIV InfectionsHIV-1HumansMaleMolecular Sequence DataPhylogenyPolymerase Chain ReactionSequence AlignmentSequence Analysis, DNASubstance Abuse, IntravenousViral ProteinsConceptsSeronegative injection drug usersInjection drug usersDrug usersHuman Immunodeficiency Virus Type 1 EnvCross-sectional studyPolymerase chainHIV-1 genesThird hypervariable regionAbility of virusesV3 loopMucosal surfacesIntersubject variationEnvelope regionInfected cellsAmino acid variationsEnvP17gagSeminal fluidVirusAcid variationsHypervariable regionInfectionDisease